Engineering Commons^™

A Multi-Objective Evaluation Of Pc Plants With Aqueous Amine Carbon Capture Systems, John Eslick

CO2 Summit: Technology and Opportunity

No abstract provided.

Lifecycle Energy Modeling - Input Into Upstream Design Process, Prasanth Chandrahasan

CO2 Summit: Technology and Opportunity

No abstract provided.

Development Of Recombinant Protein Based Chemical Conjugate Malaria Vaccines Targeting The Pre-Erythrocytic Stage, Transmission Blocking, Or Both, David L. Narum, Nicholas Macdonald, David Jones, Ruth Ellis, Yimin Wu, Patrick E. Duffy

Vaccine Technology III

The development of a Plasmodium falciparum malaria vaccine is critical for future control and elimination programs. Recombinant protein based chemical conjugate vaccines, covering different parasite stages, are being developed due to complexity of the parasite and sub-optimal immunogenicity of recombinant malaria proteins in humans, respectively. Chemical conjugation of recombinant malaria proteins to carrier proteins improves their immunogenicity in animal studies. A transmission blocking vaccine comprised of the ookinete protein Pfs25 chemically conjugated to Pseudomonas aeruginosa ExoProtein A (EPA) is currently being developed for pilot scale cGMP production. Bulk lots of Pfs25 and EPA have already been produced and released following …

Enhanced Photosynthetic Growth, Biodiesel And Electricity Production Using C. Vulgaris And P. Putida/S. Cerevisiae, Pranabendu Mitra

CO2 Summit: Technology and Opportunity

No abstract provided.

Biofuels And Bio-Based Chemicals: Opportunities & Barriers, Joseph B. Powell

CO2 Summit: Technology and Opportunity

No abstract provided.

Manufacturing Flu Vaccine In Mexico: A Major Public Health And Technology Transfer Challenge, Roger Vinas

Vaccine Technology III

As Health partner of Mexican Public authorities initiative, Sanofi Pasteur is committed to build a Flu Bulk Vaccine Site, on Mexican soil, in order, for this country, to be self-sufficient for supplying seasonal vaccine and, especially,in case of a Flu Pandemic event. This presentation will give highlights on key drivers to consider while transferring this kind of Technology from Europe to Mexico: - Technology Transfer guidelines: stepwise process - Getting Permits/Authorizations - Looking for partners/Contractors: Engineering and Construction phases - Staffing ramp-up for Manufacturing (Production and Quality Control) start-up

Challenges And Opportunities In Developing A Sustainable Biomass Infrastructure, Prabhakar Nair

CO2 Summit: Technology and Opportunity

No abstract provided.

Analysis Of Global Warming Mitigation By White Reflecting Surfaces, Federico Rossi

CO2 Summit: Technology and Opportunity

No abstract provided.

Co2 Conversion To Organic Compounds And Polymeric Precursors, Jussara Lopes De Miranda

CO2 Summit: Technology and Opportunity

No abstract provided.

Sustainable And Innovative Processes For Carbon Capture And Recycling, Manuel Alvarez-Guerra

CO2 Summit: Technology and Opportunity

No abstract provided.

The Role Of Technology In Energy Outlook, Nazeer Bhore

CO2 Summit: Technology and Opportunity

No abstract provided.

Energy Production In A Carbon-Constrained World, George Richards

CO2 Summit: Technology and Opportunity

No abstract provided.

Design Of Experiment Based Japanese Encephalitis Virus Formaldehyde Inactivation Optimisation For A Vero Cell Derived Vaccine, Michael Hughson

Vaccine Technology III

Japanese Encephalitis (JE) is a disease primarily dominant in South East Asia, caused by the Japanese Encephalitis virus (JEV). It is responsible for an estimated 50,000 cases of the disease every year, of which around 10,000 are fatal and approximately 15,000 result in long term neurological sequelae (WHO 2006). Viral inactivation is a main feature in many vaccine manufacturing processes in order not only to inactivate the product itself but also any potential adventitious agents which may have been introduced during manufacture. Chemical inactivation using formaldehyde is one of the most common methods used for inactivated viral vaccines, yet due …

New Vaccine Technologies: Promising Advances May Save More Lives, John Boslego

Vaccine Technology III

In the past 20 years, immunization has prevented nearly 20 million deaths from vaccine-preventable infections. Despite this success, poorer countries often lack access to newer and more expensive vaccines, and vaccines are not yet available for many illnesses. PATH is working to narrow the immunization gap between developed countries and developing countries by increasing the availability of existing vaccines, reducing the lag time for adoption of recently-licensed vaccines, developing technology in support of vaccines and immunization (e.g. vaccine vial monitor, Uniject, vaccine stabilization platforms) and working with partners to develop new vaccines.

Vaccine development is expensive and manufacturers often focus …

Ultra-Scale Down Studies Of Human Cell Bioprocessing For A Prostate Cancer Vaccine Therapy - The Impact Of Capillary Shear, Juan Pablo Acosta Martinez, Katherine Lawrence, Carol Chu Mike Hoare, Stephen Ward

Vaccine Technology III

The scale-up and manufacturing of therapies based on intact whole cells presents a major challenge for development scientists and engineers due to the stress-reactive nature of these cells. The administrated cells may be characterized in terms of their membrane integrity and their surface markers and eventually their biopotency. The challenge is to process the cells at various scales and in a way which maintains these cell properties. Also during formulation the presence of cytokines produced by cells prior to their inactivation is a critical factor. This poster presents an approach to allow the rapid characterization of human cell lines in …

Escherichia Coli Plasmid Dna Fermentation: Strain And Process-Specific Effects On Vector Yield, Quality, And Transgene Expression, Aaron E. Carnes, Jeremy Luke, Justin Vincent, Clague Hodgson, James Williams

Vaccine Technology III

To commercialize DNA medicines, industrial plasmid DNA manufacturing processes are needed which meet the quality, economy, and scale requirements projected for future products. NTC has developed an inducible fed-batch fermentation process that incorporates novel cell bank and fermentation process innovations that reduce plasmid mediated metabolic burden. This process also incorporates a scalable plasmid induction profile that, in combination with vector backbone modifications that double fermentation productivity compared to existing high copy vectors such as pVAX1 and gWIZ, form a generic plasmid DNA production platform driving high plasmid yields up to 2.6 g/L, with specific yields of 5% of total dry …

Development Of Protein Capsular Matrix Vaccine (Pcmv) Technology, Kevin P. Killeen, Ann Thanawastien, Tom Griffin

Vaccine Technology III

Matrivax R&D Corp. is a start-up biotechnology company with R&D operations located in Boston, USA and a vaccine pilot facility in Haikou, China. We are developing a proprietary vaccine process that entraps polysaccharides in a cross-linked protein ‘carrier’ or matrix, termed Protein Capsular Matrix Vaccine (PCMV), as an alternative to conjugate vaccine technology. Despite highly efficacious pneumococcal vaccines such as Prevnar®, S. pneumoniae causes > 1 million deaths worldwide annually. Likewise, typhoid fever afflicts ~16 million people, resulting in 600,000 deaths despite effective vaccines such as Typhim Vi® and Ty21a. The premise is that inexpensive,efficacious polysaccharide vaccines that elicit TH-cell ‘memory’ …

Process Scale-Up And Optimization For Production Of High Efficacy Oral Rabies Vaccine, Amine Kamen, Chun Fang Shen, Stephane Lanthier, Danielle Jacob, Johnny Montes, Andrew Beresford

Vaccine Technology III

Rabies is an important causative agent of disease resulting in an acute infection of the nervous system and death of the individual. Rabies remains an important public health program in developing countries, and the indigenous threat of rabies continues in developed countries because of wildlife reservoirs. Globally, there are about 55,000 fatal human cases of rabies each year [WHO, 2007]. Control of rabies in wildlife remains an important challenge for government offices.

There are numbers of rabies vaccines commercially available for controls of wildlife rabies. However, these vaccines currently distributed to wildlife do not effectively immunize all at-risk species, especially …

Ghg Impact Of Using Fast Pyrolysis Oil For Electricity And Biofuel Generation, Tom N. Kalnes

CO2 Summit: Technology and Opportunity

No abstract provided.

A Mobile Pyrolyzer For Converting Agricultural And Forestry Residues Into Liquid Bio-Oil And Bio-Char, Franco Berruti

CO2 Summit: Technology and Opportunity

No abstract provided.

Production Of Serotype 6-Derived Recombinant Adeno-Associated Virus In Serum-Free Suspension Cultures Of Hek 293 Cells, Érica A. Schulze

Vaccine Technology III

Recombinant adeno-associated virus (rAAV) has become a promising candidate vector for gene therapy. Anchorage-dependent cells are traditionally used to produce rAAV. However, mass production to meet demands for clinical trials requires large-scale and cost-effective manufacturing processes. The key advantages of rAAV vectors are a broader tissue tropism through the use of different serotypes and a good safety profile.

In the present work, a serotype 6-derived rAAV was produced by transfection of suspension HEK293 cells in serum-free medium using three plasmids: one encoding the GFP gene flanked by ITR sequences, the second encoding the replication and capsid genes, and a third …

Rna Based Plasmid Selection System For Antibiotic-Free Plasmid Dna Vector Production, Aaron E. Carnes, Jeremy Luke, Justin Vincent, Clague Hodgson, James Williams

Vaccine Technology III

Antibiotic resistance markers, typically kanamycin resistance (kanR), allow selective retention of plasmid DNA during bacterial fermentation and are the most commonly utilized selectable markers. However, to ensure safety, regulatory agencies recommend elimination of antibiotic resistance markers from therapeutic and vaccine plasmid DNA vectors. The presence of an antibiotic resistance gene in the plasmid backbone is considered undesirable by regulatory agencies, due to: 1) the potential transfer of antibiotic resistance to endogenous microbial flora; and 2) the potential activation and transcription of the genes from mammalian promoters after cellular incorporation into the genome. Here, we describe the development and application of …

Co2 Capture & Compression Technologies, Brian Wadas

CO2 Summit: Technology and Opportunity

No abstract provided.

Influence Of Host Cell Defence During Influenza Vaccine Production In Mdck Cells, Timo Frensing, Claudius Seitz, Bjoern Heynischotto-Von-Guericke, Udo Reichl

Vaccine Technology III

For cell culture-based influenza vaccine production virus yield optimisation is of crucial importance. In particular, with the recent threat of the new H1N1 pandemic, not only seasonal vaccines but also pre-/pandemic vaccines have to be supplied in large quantities. In vivo influenza replication is limited by the immune system, but for production cell lines the impact of cellular defence mechanisms on virus yield is unknown. In influenza-infected adherent Madin-Darby canine kidney (MDCK) cells the interferon (IFN) response and subsequent induction of the antiviral state was monitored. Virus yield and host cell signalling intensity were strain-dependent. By over-expression of viral antagonists …

Potent, Rapid And Cost-Effective Influenza Vaccines Made In E. Coli, Thomas Hofstaetter

Vaccine Technology III

The traditional influenza vaccine, trivalent inactivated virus (TIV) has been in use in the United States in one form or another since the 1940s. The system for production involves injecting influenza virus into embryonated hen’s eggs, harvesting the allantoic fluid containing the virus, inactivation with formalin, disruption of the virus with non-ionic detergent, zonal centrifugation to enrich for antigen and a second inactivation step. The recent appearance of the H1N1 swine virus has provided an opportunity to test the pandemic response system established over the past ten years. What we find is that the public health system seems to work …

Study Of The Gas-Liquid Co2 Absorption In Aqueous Monoethanolamine Solutions: Development Of A New Experimental Tool, Christophe E. Wylock

CO2 Summit: Technology and Opportunity

No abstract provided.

Scale-Up Of An Intensified Process For Rad35 Adenovirus Production Using The Per.C6® Cell Substrate, Alfred Luitjens, Herman Van Herk

Vaccine Technology III

Tuberculosis is the world’s second deadliest infectious disease, with over 9 million new cases diagnosed in 2006. In collaboration with the Aeras Global Tuberculosis Vaccine Foundation, we are developing a recombinant tuberculosis adenovirus based vaccine (rAd35). Currently a series of three Phase I trials are taking place, with the first two studies indicating very promising results, safety and toleration. In November 2008 we started a Phase II study in South Africa. The manufacturing process supporting these clinical studies was developed using the PER.C6® cell substrate. With the productivity of this production process, scale-up to 10,000-liter bioreactor will be required to …

Towards Sustainable Energy: Tailored Synthesis Of Carbon-Neutral Filler Materials During Carbon Mineral Sequestration, Ah-Hyung Alissa Park

CO2 Summit: Technology and Opportunity

No abstract provided.

The Challenge Of Developing New Generation Vaccines For Control And Eradication Of Foot And Mouth Disease In South America, Susana Levy

Vaccine Technology III

Foot and mouth disease (FMD) is a highly infectious viral disease that affects food producing animals such as cattle, pigs and sheep. The FMD status given by the World Organization for Animal Health (OIE) has a huge financial impact on countries that have economies based on meat trade. In the past 15 years the MERCOSUR countries (Argentina, Brazil, Paraguay and Uruguay) have consolidated industrial processes to supply the region with safe and efficacious vaccines to prevent FMD in livestock. Control and eradication programs rely heavily on compulsory vaccination with multivalent whole virus inactivated vaccines. Currently, vaccines are industrially obtained by …

Net Energy And Greenhouse Gas Emissions Evaluation Of Biodiesel Derived From Microalgae, Liaw Y. Batan

CO2 Summit: Technology and Opportunity

No abstract provided.